NASDAQ · AURA
Aura Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AURA: Nov 05, 2026
Aura Biosciences, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.31. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.31 | $-0.25 | $-0.37 | 2 |
| Dec 2026 | $-0.33 | $-0.27 | $-0.38 | 2 |
| Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Jun 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- RTTNews · Aug 11, 11:12 AM EDTAura Posts Wider Loss In Q2, Expects Cash Runway Into FY29; Reports Phase 1b/2 Interim Data(RTTNews) – Aura Biosciences, Inc. (AURA), a clinical-stage biotechnology company, on Tuesday released financial results for the second quarter ended June 30, 2026. The company reported a wider loss, primarily reflecting higher research and development and general and administrat
- RTTNews · Jul 3, 1:15 AM EDTTop Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch(RTTNews) – Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tectonic, drawing investor attention ahead of
- RTTNews · Jun 2, 10:35 AM EDTAura Completes Enrollment In Phase 3 CoMpass Study For Bel-sar In Treating Choroidal Melanoma(RTTNews) – Aura Biosciences Inc. (AURA), a clinical-stage biotechnology company, on Monday announced completion of enrollment in the Phase 3 CoMpass trial for Bel-sar in treating early choroidal melanoma.
- MarketBeat · May 27, 4:04 PM EDTAura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances3 Small-Cap Stocks Ready to Deliver Significant GrowthAura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly
- MarketBeat · May 19, 10:02 PM EDTAura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data3 Small-Cap Stocks Ready to Deliver Significant GrowthAura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial developm
- RTTNews · May 5, 1:58 AM EDTAura Announces Pricing Of Over 39 Mln Shares At $6 Per Share(RTTNews) – Aura Biosciences Inc. (AURA), a clinical-stage biotechnology company, announced on Monday the pricing of its underwritten public offering of 39.59 million shares of common stock at $6 per share.
- RTTNews · May 4, 7:49 AM EDTAura Appoints Holles As CEO As Elisabet De Los Pinos Steps Down; Sets New Public Offering(RTTNews) – Aura Biosciences Inc. (AURA), a clinical-stage biotechnology company, announced on Monday the appointment of Natalie Holles as chief executive officer and president of the board of directors, and also provided updates on ongoing Phase 3 trials for Bel-sar in treating
- Zacks · Apr 22, 9:40 AM EDTAre Medical Stocks Lagging Aura Biosciences (AURA) This Year?Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
- Zacks · Apr 20, 9:55 AM EDTDoes Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Apr 10, 9:55 AM EDTAura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
- Zacks · Apr 6, 9:40 AM EDTIs Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aura Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.